Global Monoclonal Antibodies Pipeline Analysis

Publish Date:- Jan-2014      No Of Pages (1360)

Electronic Access - Single User License $1800 Buy Now
CD-ROM Mail Delivery $2400Buy Now
Hard Copy Mail Delivery $3000 Buy Now
Electronic Access - Multi-User License $3600 Buy Now


The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future.

There has been a continuous rise in the market for therapeutic monoclonal in recent years. In 2012, there were more than 25 monoclonals in US and the EU. Currently, there are about 10 monoclonals which have already achieved category of "blockbuster", that is they are widely used medications that have been able to generate profits of more than US$ 1 Billion (each) to companies that market them. It has been estimated that in 2012, the global sales of antibody-based therapeutic products was around US$ 55 Billion.

Global Monoclonal Antibodies Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Monoclonal Antibodies based drugs being developed for the treatment of multiple diseases. Research report covers all Monoclonal Antibodies based being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Monoclonal Antibodies market based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in “Global Monoclonal Antibodies Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Global Monoclonal Antibodies Pipeline by Clinical Phase:

• Research: 117

• Preclinical: 426

• Clinical: 11

• Phase-0: 1

• Phase-I: 183

• Phase-I/II: 35

• Phase-II: 159

• Phase-II/III: 7

• Phase-III: 64

• Preregistration: 4

• Registered: 2

• Marketed: 56

• Unknown: 7


The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future.

There has been a continuous rise in the market for therapeutic monoclonal in recent years. In 2012, there were more than 25 monoclonals in US and the EU. Currently, there are about 10 monoclonals which have already achieved category of "blockbuster", that is they are widely used medications that have been able to generate profits of more than US$ 1 Billion (each) to companies that market them. It has been estimated that in 2012, the global sales of antibody-based therapeutic products was around US$ 55 Billion.

Global Monoclonal Antibodies Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Monoclonal Antibodies based drugs being developed for the treatment of multiple diseases. Research report covers all Monoclonal Antibodies based being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Monoclonal Antibodies market based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in “Global Monoclonal Antibodies Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Global Monoclonal Antibodies Pipeline by Clinical Phase:

• Research: 117

• Preclinical: 426

• Clinical: 11

• Phase-0: 1

• Phase-I: 183

• Phase-I/II: 35

• Phase-II: 159

• Phase-II/III: 7

• Phase-III: 64

• Preregistration: 4

• Registered: 2

• Marketed: 56

• Unknown: 7

1. Global Monoclonal Antibodies Market Overview



2. Monoclonal Antibodies Clinical Development Phase: Unknown

  2.1 Overview

  2.2 Monoclonal Antibodies Drug Profile in Clinical Phase



3. Monoclonal Antibodies Clinical Development Phase: Research

  3.1 Overview

  3.2 Monoclonal Antibodies Drug Profile in Clinical Phase



4. Monoclonal Antibodies Clinical Development Phase: Preclinical

  4.1 Overview

  4.2 Monoclonal Antibodies Drug Profile in Clinical Phase



5. Monoclonal Antibodies Clinical Development Phase: Clinical

  5.1 Overview

  5.2 Monoclonal Antibodies Drug Profile in Clinical Phase



6. Monoclonal Antibodies Clinical Development Phase: Phase-0

  6.1 Overview

  6.2 Monoclonal Antibodies Drug Profile in Clinical Phase



7. Monoclonal Antibodies Clinical Development Phase: Phase-I

  7.1 Overview

  7.2 Monoclonal Antibodies Drug Profile in Clinical Phase



8. Monoclonal Antibodies Clinical Development Phase: Phase-I/II

  8.1 Overview

  8.2 Monoclonal Antibodies Drug Profile in Clinical Phase



9. Monoclonal Antibodies Clinical Development Phase: Phase-II

  9.1 Overview

  9.2 Monoclonal Antibodies Drug Profile in Clinical Phase



10. Monoclonal Antibodies Clinical Development Phase: Phase-II/III
  
  10.1 Overview

  10.2 Monoclonal Antibodies Drug Profile in Clinical Phase



11. Monoclonal Antibodies Clinical Development Phase: Phase-III

  11.1 Overview

  11.2 Monoclonal Antibodies Drug Profile in Clinical Phase



12. Monoclonal Antibodies Clinical Development Phase: Preregistration

  12.1 Overview

  12.2 Monoclonal Antibodies Drug Profile in Clinical Phase



13. Monoclonal Antibodies Clinical Development Phase: Registered

  13.1 Overview

  13.2 Monoclonal Antibodies Drug Profile in Clinical Phase



14. Marketed

  14.1 Overview

  14.2 Marketed Monoclonal Antibodies Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name